MABPAIR Trademark

Trademark Overview


On Thursday, August 6, 2020, a trademark application was filed for MABPAIR with the United States Patent and Trademark Office. The USPTO has given the MABPAIR trademark a serial number of 90098142. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Thursday, September 1, 2022. This trademark is owned by Qilu Puget Sound Biotherapeutics Corporation. The MABPAIR trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

Pharmaceutical compounds and compositions for the treatment of cancer, autoimmune diseases, metabolic disorders, hematological and neurological diseases; therapeutic agents for cancer, autoimmune diseases, metabolic disorders, hematological and neurological diseases; pharmaceutical preparations, namely, immunotherapy agents in the nature of monoclonal antibodies, medical diagnostic buffers, and reagents for use in cancer, autoimmune diseases, metabolic disorders, hematological and neurological diseases disease testing and treatment for medical purposes; all of the foregoing containing monoclonal antibodies

Pharmaceutical research and drug development; research and development related to drugs for immunotherapies; research and development services in the field of monoclonal antibodies; Providing access to a technology platform for developing custom-designed antibody combinations
mabpair

General Information


Serial Number90098142
Word MarkMABPAIR
Filing DateThursday, August 6, 2020
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateThursday, September 1, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesPharmaceutical compounds and compositions for the treatment of cancer, autoimmune diseases, metabolic disorders, hematological and neurological diseases; therapeutic agents for cancer, autoimmune diseases, metabolic disorders, hematological and neurological diseases; pharmaceutical preparations, namely, immunotherapy agents in the nature of monoclonal antibodies, medical diagnostic buffers, and reagents for use in cancer, autoimmune diseases, metabolic disorders, hematological and neurological diseases disease testing and treatment for medical purposes; all of the foregoing containing monoclonal antibodies
Goods and ServicesPharmaceutical research and drug development; research and development related to drugs for immunotherapies; research and development services in the field of monoclonal antibodies; Providing access to a technology platform for developing custom-designed antibody combinations

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, September 8, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, September 8, 2020
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameQilu Puget Sound Biotherapeutics Corporation
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressBothell, WA 98021

Trademark Events


Event DateEvent Description
Thursday, September 1, 2022ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Thursday, September 1, 2022ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Thursday, September 1, 2022ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Thursday, February 17, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, February 17, 2022NON-FINAL ACTION E-MAILED
Thursday, February 17, 2022NON-FINAL ACTION WRITTEN
Thursday, January 6, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 6, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, January 6, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, July 9, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, July 9, 2021NON-FINAL ACTION E-MAILED
Friday, July 9, 2021NON-FINAL ACTION WRITTEN
Monday, June 7, 2021ASSIGNED TO EXAMINER
Thursday, June 3, 2021TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 3, 2021CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, June 3, 2021TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, December 3, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, December 3, 2020NON-FINAL ACTION E-MAILED
Thursday, December 3, 2020NON-FINAL ACTION WRITTEN
Monday, November 30, 2020ASSIGNED TO EXAMINER
Tuesday, September 8, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, August 10, 2020NEW APPLICATION ENTERED IN TRAM